These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30987984)

  • 1. Co-prescription patterns of cardiovascular preventive treatments: a cross-sectional study in the Aragon worker' health study (Spain).
    Aguilar-Palacio I; Malo S; Lallana M; Feja C; González J; Moreno-Franco B; Rabanaque M
    BMJ Open; 2019 Apr; 9(4):e023571. PubMed ID: 30987984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
    van Peet PG; Gussekloo J; den Elzen WP; Blom JW; de Waal MW; de Ruijter W
    Scand J Prim Health Care; 2015; 33(4):260-8. PubMed ID: 26683286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare.
    Hyun KK; Redfern J; Patel A; Peiris D; Brieger D; Sullivan D; Harris M; Usherwood T; MacMahon S; Lyford M; Woodward M
    Heart; 2017 Apr; 103(7):492-498. PubMed ID: 28249996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.
    Wu J; Zhu S; Yao GL; Mohammed MA; Marshall T
    PLoS One; 2013; 8(7):e67611. PubMed ID: 23922649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription of Lipid-Lowering and Antihypertensive Drugs Following Pictorial Information About Subclinical Atherosclerosis: A Secondary Outcome of a Randomized Clinical Trial.
    Sjölander M; Carlberg B; Norberg M; Näslund U; Ng N
    JAMA Netw Open; 2021 Aug; 4(8):e2121683. PubMed ID: 34410393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level.
    Roccatagliata D; Avanzini F; Monesi L; Caimi V; Lauri D; Longoni P; Marchioli R; Tombesi M; Tognoni G; Roncaglioni MC;
    Vasc Health Risk Manag; 2006; 2(4):507-14. PubMed ID: 17323606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Variations in the prescription of antibiotics among primary care areas in the autonomous region of Aragon, Spain].
    Lallana Alvarez MJ; Feja Solana C; Malo Fumanal S; Abad Diez JM; Bjerrum L; Rabanaque Hernández MJ;
    Rev Esp Salud Publica; 2012 Dec; 86(6):627-35. PubMed ID: 23325137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
    Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription patterns of lipid lowering agents among older patients in general practice: an analysis from a national database in the Netherlands.
    Kleipool EEF; Nielen MMJ; Korevaar JC; Harskamp RE; Smulders YM; Serné E; Thijs A; Peters MJL; Muller M
    Age Ageing; 2019 Jul; 48(4):577-582. PubMed ID: 31074492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study.
    Márquez PHP; Torres OH; San-José A; Vidal X; Agustí A; Formiga F; López-Soto A; Ramírez-Duque N; Fernández-Moyano A; Garcia-Moreno J; Arroyo JA; Ruiz D;
    Drugs Aging; 2017 Jun; 34(6):453-466. PubMed ID: 28432600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
    Tomasik T; Windak A; Seifert B; Kersnik J; Kijowska V; Dubas K
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):234-42. PubMed ID: 23277158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular disease and all-cause mortality in people with screen-detected diabetes: findings from the ADDITION-Denmark trial.
    Simmons RK; Carlsen AH; Griffin SJ; Charles M; Christiansen JS; Borch-Johnsen K; Sandbaek A; Lauritzen T
    Diabet Med; 2014 Dec; 31(12):1577-85. PubMed ID: 25185778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia.
    Banks E; Crouch SR; Korda RJ; Stavreski B; Page K; Thurber KA; Grenfell R
    Med J Aust; 2016 May; 204(8):320. PubMed ID: 27125809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of the utilization of angiotensin receptor blockers in hypertension].
    Peña Cabia S; Ricote Lobera I; Santos Mena B; Hidalgo Correas FJ; Climent Florez B; García Díaz B
    Farm Hosp; 2013; 37(5):394-8. PubMed ID: 24128102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.
    Moreno-Arellano S; Delgado-de-Mendoza J; Santi-Cano MJ
    Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):810-815. PubMed ID: 29754716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of rational nonsteroidal anti-inflammatory drugs and gastro-protective agents use; association rule data mining using outpatient prescription patterns.
    Pattanaprateep O; McEvoy M; Attia J; Thakkinstian A
    BMC Med Inform Decis Mak; 2017 Jul; 17(1):96. PubMed ID: 28676124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editor's Choice - Optimal Pharmacological Treatment of Symptomatic Peripheral Arterial Occlusive Disease and Evidence of Female Patient Disadvantage: An Analysis of Health Insurance Claims Data.
    Peters F; Kreutzburg T; Rieß HC; Heidemann F; Marschall U; L'Hoest H; Debus ES; Sedrakyan A; Behrendt CA
    Eur J Vasc Endovasc Surg; 2020 Sep; 60(3):421-429. PubMed ID: 32669223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in nonagenarians: Prevalence and utilization of preventive therapies.
    Mostaza JM; Lahoz C; Salinero-Fort MA; Cardenas J
    Eur J Prev Cardiol; 2019 Mar; 26(4):356-364. PubMed ID: 30426771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark.
    Graversen L; Christensen B; Borch-Johnsen K; Lauritzen T; Sandbaek A
    Scand J Prim Health Care; 2010 Mar; 28(1):47-54. PubMed ID: 19929180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.